Company Profile
Crinetics Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- CRNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
83.92 USD (-0.10%)
Close
Last updated: August 6, 2026
3.44B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRNX was little changed and closed at $83.92. No new same-company headline was identified in the current news window.
Company overview
Endocrine-Focused Pharmaceuticals
Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.
PALSONIFY
PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It is designed to provide an oral alternative to injected peptide treatments.
Congenital Adrenal Hyperplasia
Crinetics is also developing therapies for congenital adrenal hyperplasia, including a pediatric program being evaluated in the Phase 2/3 BALANCE-CAH study.
Future catalysts
Crinetics's catalysts are paltusotine in acromegaly and atumelnant in endocrine disease, where the next clinical and regulatory steps can keep the endocrine story moving. The company is still building toward a broader hormone-franchise.
Recent news
- 01
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Crinetics Pharmaceuticals
- 02
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
Source: Crinetics Pharmaceuticals
- 03
- 04
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Source: Crinetics Pharmaceuticals
- 05
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
Source: Crinetics Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Crinetics Pharmaceuticals (CRNX)?
Crinetics Pharmaceuticals (CRNX) most recently closed at 83.92 USD, a -0.10% move versus the previous session.
What is the market cap of Crinetics Pharmaceuticals (CRNX)?
Crinetics Pharmaceuticals currently has a market capitalization of 3.44B USD on BioPharmSignal.
What does Crinetics Pharmaceuticals do?
Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors. PALSONIFY PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It...
On which exchange is CRNX stock listed?
Crinetics Pharmaceuticals (CRNX) is associated with NASDAQ, United States, Biopharma.
What is BALANCE-CAH?
Congenital Adrenal Hyperplasia Crinetics is also developing therapies for congenital adrenal hyperplasia, including a pediatric program being evaluated in the Phase 2/3 BALANCE-CAH study.
Which conditions is Crinetics Pharmaceuticals targeting with BALANCE-CAH?
Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors. PALSONIFY PALSONIFY, or paltusotine, is an oral somatostatin receptor type 2 agonist commercialized for acromegaly. It...
How does Crinetics Pharmaceuticals describe recent progress with BALANCE-CAH?
Crinetics's catalysts are paltusotine in acromegaly and atumelnant in endocrine disease, where the next clinical and regulatory steps can keep the endocrine story moving. The company is still building toward a broader hormone-franchise.
What is Endocrine-Focused?
Endocrine-Focused Pharmaceuticals Crinetics Pharmaceuticals discovers, develops and commercializes therapies for endocrine diseases and endocrine-related tumors, with core expertise in small molecules targeting G-protein-coupled receptors.